Alefacept
- Generic Name
- Alefacept
- Drug Type
- Biotech
- CAS Number
- 222535-22-0
- Unique Ingredient Identifier
- ELK3V90G6C
- Background
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
- Indication
As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis
Alefacept in Patients With Severe Scalp Alopecia Areata
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 45
- Registration Number
- NCT00167102
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Alefacept Mechanism of Action in Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-08-07
- Target Recruit Count
- 9
- Registration Number
- NCT00150982
- Locations
- 🇺🇸
UMDNJ Clinical Research Center, New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath